ProfileGDS4814 / ILMN_1698060
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 49% 46% 60% 30% 20% 25% 19% 25% 14% 32% 12% 12% 23% 27% 23% 32% 8% 23% 28% 31% 22% 13% 35% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)50.141349
GSM780708Untreated after 4 days (C2_1)49.347846
GSM780709Untreated after 4 days (C3_1)55.419960
GSM780719Untreated after 4 days (C1_2)45.533330
GSM780720Untreated after 4 days (C2_2)43.523620
GSM780721Untreated after 4 days (C3_2)44.54825
GSM780710Trastuzumab treated after 4 days (T1_1)43.447419
GSM780711Trastuzumab treated after 4 days (T2_1)44.482325
GSM780712Trastuzumab treated after 4 days (T3_1)42.233914
GSM780722Trastuzumab treated after 4 days (T1_2)45.92132
GSM780723Trastuzumab treated after 4 days (T2_2)41.734812
GSM780724Trastuzumab treated after 4 days (T3_2)41.799412
GSM780713Pertuzumab treated after 4 days (P1_1)44.210723
GSM780714Pertuzumab treated after 4 days (P2_1)45.067727
GSM780715Pertuzumab treated after 4 days (P3_1)44.179623
GSM780725Pertuzumab treated after 4 days (P1_2)45.937732
GSM780726Pertuzumab treated after 4 days (P2_2)40.71518
GSM780727Pertuzumab treated after 4 days (P3_2)44.149323
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)45.270828
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)45.72331
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)44.009322
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)42.092613
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)46.569635